1.55
Precedente Chiudi:
$1.53
Aprire:
$1.54
Volume 24 ore:
121.57K
Relative Volume:
0.36
Capitalizzazione di mercato:
$66.48M
Reddito:
$51.13M
Utile/perdita netta:
$-93.80M
Rapporto P/E:
-0.6951
EPS:
-2.23
Flusso di cassa netto:
$-129.10M
1 W Prestazione:
+1.97%
1M Prestazione:
+9.15%
6M Prestazione:
+27.05%
1 anno Prestazione:
-60.05%
Repare Therapeutics Inc Stock (RPTX) Company Profile
Nome
Repare Therapeutics Inc
Settore
Industria
Telefono
(857) 412-7018
Indirizzo
7171 FREDERICK BANTING, SAINT-LAURENT, QC
Confronta RPTX con altri titoli
Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
---|---|---|---|---|---|---|
![]()
RPTX
Repare Therapeutics Inc
|
1.55 | 65.62M | 51.13M | -93.80M | -129.10M | -2.23 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
472.27 | 120.73B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
564.64 | 61.80B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
328.00 | 42.46B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ARGX
Argen X Se Adr
|
591.74 | 35.22B | 2.58B | 1.06B | -1.28B | 16.33 |
![]()
ONC
Beone Medicines Ltd Adr
|
296.46 | 31.99B | 3.81B | -644.79M | -669.77M | -6.24 |
Repare Therapeutics Inc Stock (RPTX) Upgrades & Downgrades
Data | Azione | Analista | Modifica della valutazione |
---|---|---|---|
2023-06-09 | Aggiornamento | Stifel | Hold → Buy |
2023-02-03 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
2023-01-06 | Iniziato | CapitalOne | Overweight |
2022-04-12 | Downgrade | Stifel | Buy → Hold |
2022-03-17 | Ripresa | Goldman | Buy |
2021-09-23 | Iniziato | Stifel | Buy |
2021-09-13 | Iniziato | H.C. Wainwright | Buy |
2021-06-28 | Iniziato | Guggenheim | Buy |
2021-03-01 | Iniziato | Berenberg | Buy |
2020-10-28 | Iniziato | Northland Capital | Outperform |
2020-07-14 | Iniziato | Cowen | Outperform |
2020-07-14 | Iniziato | Goldman | Neutral |
2020-07-14 | Iniziato | Morgan Stanley | Overweight |
2020-07-14 | Iniziato | Piper Sandler | Overweight |
Mostra tutto
Repare Therapeutics Inc Borsa (RPTX) Ultime notizie
Is Repare Therapeutics Inc. a good long term investmentMassive portfolio appreciation - PrintWeekIndia
Why Repare Therapeutics Inc. stock is on top investor watchlistsUnrivaled growth potential - jammulinksnews.com
What analysts say about Repare Therapeutics Inc. stock outlookMarket-leading growth rates - jammulinksnews.com
Will Repare Therapeutics Inc. stock benefit from interest rate changesDynamic growth stocks - jammulinksnews.com
What drives Repare Therapeutics Inc. stock priceExponential return rates - jammulinksnews.com
What analysts say about Repare Therapeutics Inc. stockRecord-breaking gains - jammulinksnews.com
Why Repare Therapeutics Inc. stock attracts strong analyst attentionFree Access to Community - Newser
Repare Therapeutics Inc. Stock Analysis and ForecastUnprecedented growth rates - jammulinksnews.com
what makes repare therapeutics inc. stock price move sharplyLow Risk Profit Ideas - Newser
Layoff Tracker: Following Challenges With DMD Therapy, Sarepta Will Cut 500 Employees - BioSpace
Repare Therapeutics Jumps 15% After $10M Licensing Deal With Debiopharm - Yahoo Finance
How Repare Therapeutics Inc. stock performs during market volatilityBig Profit Small Risk Alerts - Newser
Repare Therapeutics Jumps 15% After $10M Licensing Deal With Deb - GuruFocus
Repare Therapeutics Licenses Lunresertib to Debiopharm for Worldwide Development. - AInvest
Deal Watch: Debiopharm Takes On Precision Oncology Drug From Repare Collab - insights.citeline.com
Repare inks licensing deal with Debiopharm for lunresertib - The Pharma Letter
Repare Therapeutics Jumps After Hours On $267M Global Licensing Deal With Debiopharm; Retail Traders Rush In - Stocktwits
how repare therapeutics inc. stock performs during market volatilityFast Moving Stock Alerts - Newser
Repare Therapeutics' Lunresertib Deal: A Strategic Pivot to Unlock Oncology Potential and Near-Term Catalysts - AInvest
Repare Therapeutics stock surges after $10M licensing deal with Debiopharm By Investing.com - Investing.com South Africa
What makes Repare Therapeutics Inc. stock price move sharplyHigh Reward Risk Balanced Trading - Newser
Repare Therapeutics stock surges after $10M licensing deal with Debiopharm - Investing.com Nigeria
Repare Therapeutics Inc. Enters Exclusive Worldwide Licensing Agreement with Debiopharm for Lunresertib - MarketScreener
Repare Therapeutics (RPTX) Secures Global Licensing Deal with Debiopharm | RPTX Stock News - GuruFocus
Repare Therapeutics enters exclusive worldwide licensing agreement with Debiopharm for Lunresertib - MarketScreener
Repare Therapeutics licenses PKMYT1 inhibitor to Debiopharm for $10 million - Investing.com Nigeria
Repare Therapeutics jumps on cancer drug licensing deal - TradingView
Repare Therapeutics Enters Exclusive Worldwide Licensing Agreement with Debiopharm for Lunresertib | RPTX Stock News - GuruFocus
Repare Therapeutics Enters Exclusive Worldwide Licensing Agreement with Debiopharm for Lunresertib - Business Wire
Repare Therapeutics Inc Azioni (RPTX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):